Ambrx Report issue

For profit Phase 1 Phase 2
Founded: La Jolla CA United States (2003)
Status: Acquired by Fosun (2015)

Organization Overview

First Clinical Trial
2006
NCT01412658
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ambrx, Inc. | Ambryx Biotechnology

Active Ingredients

Drugs in Phase 2 Trials (2)

arx201 (1 trial)

arx788 (4 trials)

Drugs in Phase 1 Trials (2)

arx517 (1 trial)

hydrolyzed milk protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Dwarfism, Pituitary (Phase 2)

Endocrine System Diseases (Phase 2)

Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4